| Literature DB >> 34715894 |
Yu-Hua Huang1,2,3,4, Chunfeng Fang3, Tao Yang1,3, Lin Cao3, Gaolong Zhang4, Baolin Qu1, Yihang Zhang4, Zishen Wang3, Shouping Xu5,6.
Abstract
BACKGROUND: In the existing application of beam-matched multiroom proton therapy system, the model based on the commissioning data from the leading treatment room was used as the shared model. The purpose of this study is to investigate the ability of independently-tuned room-specific beam models of beam-matched gantries to reproduce the agreement between gantries' performance when considering the errors introduced by the modeling process.Entities:
Keywords: Beam analysis; Beam-matching; Monte Carlo; Pencil beam scanning; Proton therapy
Mesh:
Year: 2021 PMID: 34715894 PMCID: PMC8555324 DOI: 10.1186/s13014-021-01932-0
Source DB: PubMed Journal: Radiat Oncol ISSN: 1748-717X Impact factor: 3.481
Fig. 1Effective energy spectra and R80/nominal energy difference of GTR2 and GTR4
Fig. 2Mean γ indices of each nominal energy in cross-gantry comparisons
Fig. 3Representative examples of: intra-gantry comparisons between measured and computed IDD curves for each gantry (a, b), and cross-gantry comparisons of IDD curves between GTR2 and GTR4 (c, d)
Fig. 4Comparison of the spatial-angular distribution moments for each energy at the isocenter
Fig. 5Intra-gantry comparisons between measured and computed spot profile for each gantry (a, b). Cross-gantry comparisons of spot profile between GTR2 and GTR4 (c, d)
Site-distinguished γ results of patient-specific QA
| Beam model | Delivered gantry | Malignancy | Criteria | Mean passing rate (%) | Range |
|---|---|---|---|---|---|
| Shared GTR2 model | GTR2 (M2G2) | Prostate | 2 mm/3% | 96.83 | 90.6–99.4 |
| 3 mm/3% | 98.98 | 96.7–100.0 | |||
| Lung | 2 mm/3% | 97.67 | 94.3–100.0 | ||
| 3 mm/3% | 99.06 | 97.4–100.0 | |||
| NPC | 2 mm/3% | 98.36 | 92.3–100.0 | ||
| 3 mm/3% | 99.69 | 97.9–100.0 | |||
| GTR4 (M2G4) | Prostate | 2 mm/3% | 97.25 | 92.8–99.9 | |
| 3 mm/3% | 99.00 | 96.7–100.0 | |||
| Lung | 2 mm/3% | 97.91 | 93.7–100.0 | ||
| 3 mm/3% | 99.19 | 97.4–100.0 | |||
| NPC | 2 mm/3% | 98.24 | 92.1–100.0 | ||
| 3 mm/3% | 99.58 | 98.3–100.0 | |||
| Shared GTR4 model | GTR2 (M4G2) | Prostate | 2 mm/3% | 96.74 | 90.8–99.9 |
| 3 mm/3% | 98.91 | 96.7–100.0 | |||
| Lung | 2 mm/3% | 97.26 | 92.6–100.0 | ||
| 3 mm/3% | 98.91 | 96.6–100.0 | |||
| NPC | 2 mm/3% | 98.44 | 93.0–100.0 | ||
| 3 mm/3% | 99.46 | 96.3–100.0 | |||
| GTR4 (M4G4) | Prostate | 2 mm/3% | 97.34 | 93.9–99.7 | |
| 3 mm/3% | 99.10 | 96.7–100.0 | |||
| Lung | 2 mm/3% | 97.81 | 94.1–100.0 | ||
| 3 mm/3% | 98.99 | 96.7–100.0 | |||
| Head | 2 mm/3% | 98.49 | 93.1–100.0 | ||
| 3 mm/3% | 99.41 | 96.4–100.0 |
Statistical analysis results of patient-specific QA
| Comparison | Malignancy | Criteria | Difference (%) | t/ | |
|---|---|---|---|---|---|
| M2G2 versus M4G2 | Prostate | 2 mm/3% | 0.09 | 0.442/0.661 | 0.847(0.00) |
| 3 mm/3% | 0.07 | 0.907/0.371 | 0.866(0.00) | ||
| Lung | 2 mm/3% | 0.41 | 1.992/0.054 | 0.829(0.00) | |
| 3 mm/3% | 0.15 | 1.306/0.200 | 0.754(0.00) | ||
| NPC | 2 mm/3% | − 0.09 | − 0.229/0.820 | 0.432(0.00) | |
| 3 mm/3% | 0.22 | 1.865/0.071 | 0.604(0.00) | ||
| M2G4 versus M4G4 | Prostate | 2 mm/3% | − 0.09 | − 0.705/0.486 | 0.916(0.00) |
| 3 mm/3% | − 0.10 | − 1.399/0.171 | 0.865(0.00) | ||
| Lung | 2 mm/3% | 0.10 | 0.470/0.641 | 0.788(0.00) | |
| 3 mm/3% | 0.21 | 1.788/0.082 | 0.732(0.00) | ||
| NPC | 2 mm/3% | − 0.25 | − 0.809/0.424 | 0.589(0.00) | |
| 3 mm/3% | 0.17 | 1.367/0.180 | 0.575(0.00) |